Craig Martin is CEO of health strategy and communications firm Feinstein Kean Healthcare (FKH), an Ogilvy company based in Cambridge, MA, with offices in other life science, health and technology hubs around the country. He also serves as a Global Principal for Ogilvy RED, the agency’s consulting arm, leading the RED’s work in Biotech and Health Technology. Craig is an advisor to leading and emerging biotech, pharmaceutical, diagnostic, health IT and other companies and advocacy organizations. His background includes managing businesses, teams and consultancies based in Cambridge, New York, Washington, DC, and Brussels. During the past decade in particular, Craig has spent considerable time working with companies and non-profit groups focused in rare disease and oncology. He has also been a speaker and advisor on shifting advocacy models that reflect the new role of patients and their data in biomedical research and development. In addition to serving on the FCF board, Craig also serves on the board of Global Genes, a rare disease advocacy organization.